Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: Combined ligand and target-based approach

被引：126

作者：

Gundla, Rambabu ^{[1
]}

Kazemi, Roza ^{[1
]}

Sanam, Ramadevi ^{[2
]}

Muttineni, Ravikumar ^{[2
]}

Sarma, Jagarlapudi A. R. P. ^{[2
]}

Dayam, Raveendra ^{[1
]}

Neamati, Nouri ^{[1
]}

机构：

[1] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA

[2] GVK Biosci Pvt Ltd, Div Informat, Technocrats Ind Estate, Hyderabad, Andhra Pradesh, India

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2008年 / 51卷 / 12期

关键词：

D O I：

10.1021/jm7013875

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Consensus virtual screening models were generated and validated utilizing a set of known human epidermal growth factor receptor-2 (HER2) inhibitors and modeled HER2 active and inactive state structures. The virtual screening models were successfully employed to discover a set of structurally diverse compounds with growth inhibitory activity against HER2-overexpressing SKBR3 breast cancer cell line. A search of a 3D database containing 350000 small-molecules using the consensus models retrieved 531 potential hits. Of the 531 hits, 57 were selected for testing in SKBR3 cells on the basis of structural novelty and desirable drug-like properties. Seven compounds inhibited growth of SKBR3 cells with IC50 values <10 mu M. These lead compounds have desirable physicochemical properties and are excellent candidates for further optimization.

引用

页码：3367 / 3377

页数：11

共 42 条

[11] Therapeutically targeted anticancer agents:: Inhibitors of receptor tyrosine kinases [J].

García-Echeverria, C ;

Fabbro, D .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (03) :273-283

[12] The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors [J].

Garrett, TPJ ;

McKern, NM ;

Lou, MZ ;

Elleman, TC ;

Adams, TE ;

Lovrecz, GO ;

Kofler, M ;

Jorissen, RN ;

Nice, EC ;

Burgess, AW ;

Ward, CW .

MOLECULAR CELL, 2003, 11 (02) :495-505

[13] Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines [J].

Gaul, MD ;

Guo, Y ;

Affleck, K ;

Cockerill, GS ;

Gilmer, TM ;

Griffin, RJ ;

Guntrip, S ;

Keith, BR ;

Knight, WB ;

Mullin, RJ ;

Murray, DM ;

Rusnak, DW ;

Smith, K ;

Tadepalli, S ;

Wood, ER ;

Lackey, K .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (04) :637-640

[14] TYRPHOSTINS .2. HETEROCYCLIC AND ALPHA-SUBSTITUTED BENZYLIDENEMALONONITRILE TYRPHOSTINS AS POTENT INHIBITORS OF EGF RECEPTOR AND ERBB2/NEU TYROSINE KINASES [J].

GAZIT, A ;

OSHEROV, N ;

POSNER, I ;

YAISH, P ;

PORADOSU, E ;

GILON, C ;

LEVITZKI, A .

JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (06) :1896-1907

[15] Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel [J].

Gril, Brunilde ;

Vidal, Michel ;

Assayag, Franck ;

Poupon, Marie-France ;

Liu, Wang-Qing ;

Garbay, Christiane .

INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (02) :407-415

[16] INSECT CELL-EXPRESSED P180(ERBB3) POSSESSES AN IMPAIRED TYROSINE KINASE-ACTIVITY [J].

GUY, PM ;

PLATKO, JV ;

CANTLEY, LC ;

CERIONE, RA ;

CARRAWAY, KL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (17) :8132-8136

[17]

*GVK BIOSC PVT LTD, KIN DAT INF

[18] ERBB receptors and cancer: The complexity of targeted inhibitors [J].

Hynes, NE ;

Lane, HA .

NATURE REVIEWS CANCER, 2005, 5 (05) :341-354

[19] Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors [J].

Jin, Y ;

Li, HY ;

Lin, LP ;

Tan, JZ ;

Ding, J ;

Luo, XM ;

Long, YQ .

BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (19) :5613-5622

[20] Binding specificities and affinities of egf domains for ErbB receptors [J].

Jones, JT ;

Akita, RW ;

Sliwkowski, MX .

FEBS LETTERS, 1999, 447 (2-3) :227-231

← 1 2 3 4 5 →